NCT05907291 - Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

August 22, 2025

Study Completion Date

August 22, 2025

Conditions

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia

Interventions

DRUG

atumelnant (CRN04894)

Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

Trial Locations (27)

5000

Crinetics Study Site, Córdoba

19104

Crinetics Study Site, Philadelphia

20089

Crinetics Study Site, Rozzano

28557

Crinetics Study Site, Morehead City

44195

Crinetics Study Site, Cleveland

48109

Crinetics Study Site, Ann Arbor

55454

Crinetics Study Site, Minneapolis

63110

Crinetics Study Site, St Louis

80131

Crinetics Study Site, Napoli

80336

Crinetics Study Site, Munich

91105

Crinetics Study Site, Pasadena

560054

Crinetics Study Site, Bangalore

632004

Crinetics Study Site, Vellore

02915

Crinetics Study Site, East Providence

C1180

Crinetics Study Site, Buenos Aires

80030-110

Crinetics Study Site, Curitiba

20231-092

Crinetics Study Site, Rio de Janeiro

20551-030

Crinetics Study Site, Rio de Janeiro

90410-000

Crinetics Study Site, Porto Alegre

18618-686

Crinetics Study Site, Botucatu

14051-140

Crinetics Study Site, Ribeirão Preto

04024-002

Crinetics Study Site, São Paulo

05403-000

Crinetics Study Site, São Paulo

00161

Crinetics Study Site, Roma

S10 2RX

Crinetics Study Site, Sheffield

CV22DX

Crinetics Study Site, Coventry

NW1 2PG

Crinetics Study Site, London